The federal agency is requiring all GLP-1s to include information about the potential risk on warning labels

The US Food and Drug Administration (FDA) has issued a new warning on GLP-1 medications – which can facilitate weight loss – over a rare eye condition that could lead to sudden and permanent blindness.

On Monday, the FDA announced that it is requiring all GLP-1 medications – including Novo Nordisk’s Ozempic and Wegovy, Eli Lilly’s Mounjaro and Zepbound, as well as Sanofi’s Soliqua – to include information about the potential risk of nonarteritic anterior ischemic optic neuropathy, also known as NAION, on warning labels.

Continue reading…

Published by Archie Watson on 10 November 2026. GEMHerald summarises reporting from other outlets and links to the original. Read our editorial policy and how we handle corrections.